Shingrix is a vaccine that protects adults from shingles and was developed by GlaxoSmithKline. It is made of a recombinant antigen and an adjuvant that stimulate the immune system. Clinical trials show the vaccine’s effectiveness as 97% in adults over 50, higher than the previous vaccine that showed 51% effectiveness in adults aged 60 and above. Shingrix provides long-lasting protection that lasts up to six years, and the two-dose vaccine can be given to anyone over 50, even those who have never had shingles. It is particularly important for people with weak immune systems and those who have had shingles before.